Quality of Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Non-valvular Atrial Fibrillation
Clinical Trials Monday, March 11th, 2013Science Direct: February 28, 2013
Background
The PROTECT AF trial demonstrated that in patients with non-valvular AF and CHADS2 ≥ 1, a LAA closure device is non-inferior to long-term warfarin for stroke prevention. Given this equivalency, quality of life (QOL) indicators are an important metric for evaluating these two different strategies.
Methods
QOL using the SF-12-V2 measurement tool was obtained at baseline and 12 months in a subset of 547 patients in the PROTECT AF Trial (361 device and 186 warfarin patients). The analysis cohort consisted of those for whom either paired quality of life data was available after 12 months follow-up or in patients that died. Read more
